COLLAGEN STOCK ADVANCES 17% TO 19-3/4 IN AUGUST AS FIRM PREDICTS 1997 IMPROVEMENT FROM AESTHETIC TECHNOLOGIES BUSINESS; O-T-C INDEX RECOUPS 4.4%
This article was originally published in The Gray Sheet
Executive SummaryCollagen's ability to weather lower Contigen incontinence implant sales in fiscal 1996, combined with the firm's predicted improvement in operating income in 1997, apparently helped inspire investor confidence in the stock. The issue reversed a two month slide and advanced 2-7/8 points, or 17%, to 19-3/4 in August, regaining some ground it relinquished in June and July, when it lost more than 20% of its value.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.